Change over period: —
NSE · ALKEM
ALKEM
-11.3% from the 52-week high · +5.6% above the low
Alkem Laboratories Ltd. engages in the development, manufacture, and sale of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 16,871 full-time employees. The company went IPO on 2015-12-23. The firm is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The firm offers its products across various therapeutic areas, such as Anti Infective, Dermatology, Diabetology, Cardiology, Gastroenterology, Osteoporosis, Rheumatology, central nervous system (CNS), Oncology, Urology, Gynecology, and Vitamins, Mineral and Nutrition. Its product range includes Rx Products, Alkem Generics and OTC Product. The Company’s product portfolio includes brands, such as Clavam, Pan, Pan-D, Taxim-O, A To Z NS, Xone, Taxim, Gemcal, Pipzo and Ondem. The firm operates through a segment, Pharmaceuticals. The company has approximately 21 manufacturing facilities at multiple locations in India and the United States. The firm has approximately 800 brands and operates in 40 countries.
The short version. ALKEM reported revenue of ₹4,552 crore for Sep 2026, up 13.8% from a year earlier. Net profit was ₹675 crore (down 11.8% year on year). Return on equity was 16.7% in Mar 2026. Promoter holding was 49.7% in Jun 2026, down 5.96 points over 8 quarters.
1 · The price
How has the stock traded?
ALKEM trades 11.3% below its 52-week high and 5.6% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹4,552 cr.
Sep 2026 net profit of ₹675 cr.
4.3 pts lower than a year earlier.
Revenue compounded at 9.0% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4552 | 3740 | 3603 | 3737 | 4001 | 3371 | 3144 | 3374 |
| Net profit | 675 | 520 | 236 | 636 | 765 | 664 | 306 | 626 |
| Net margin % | 14.8 | 13.9 | 6.6 | 17.0 | 19.1 | 19.7 | 9.7 | 18.5 |
| EPS (₹) | 56.48 | 43.49 | 19.78 | 53.19 | 63.99 | 55.56 | 25.58 | 52.34 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14712 | 12965 | 12668 | 11599 | 10634 | 8865 | 8344 | 7357 |
| Net profit | 2302 | 2165 | 1796 | 984 | 1646 | 1585 | 1127 | 761 |
| Net margin % | 15.6 | 16.7 | 14.2 | 8.5 | 15.5 | 17.9 | 13.5 | 10.3 |
| EPS (₹) | 192.51 | 181.11 | 150.19 | 82.31 | 137.63 | 132.57 | 94.26 | 63.61 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 16.7% in Mar 2026; debt to equity is 0.12.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 16.7 | 18.1 | 17.4 | 10.9 |
| Return on capital % | 18.8 | 19.3 | 18.4 | 14.1 |
| EBITDA margin % | 22.3 | 22.3 | 18.8 | 14.6 |
| Net margin % | 15.0 | 16.1 | 13.8 | 8.3 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 9.0% | 10.9% |
| Profit CAGR | 32.7% | 7.8% |
4 · The owners
Who holds it, and are they adding?
Down 5.96 pts over 8 quarters.
Up 1.4 pts over 8 quarters.
Up 3.42 pts over 8 quarters.
+45 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 55.66 | 55.66 | 55.13 | 53.04 | 51.2 | 51.2 | 51.2 | 49.7 | -5.96 |
| FII | 9.02 | 10.15 | 9.41 | 9.11 | 9.48 | 9.97 | 10.16 | 10.42 | +1.4 |
| DII | 19.21 | 18.01 | 19.42 | 21.8 | 21.93 | 21.54 | 21.4 | 22.63 | +3.42 |
| Public | 16.1 | 16.18 | 16.05 | 16.05 | 17.4 | 17.3 | 17.25 | 17.25 | +1.15 |
Mutual fund holdings · Oct 2026
205 schemes hold this stock
160 the month before.
- HDFC Pharma and Healthcare Fund4.75% of NAV
- DSP Healthcare Fund4.73% of NAV
- TATA NIFTY MIDSMALL HEALTHCARE INDEX FUND4.65% of NAV
- Motilal Oswal Nifty MidSmall Healthcare Index Fund4.64% of NAV
- ICICI Prudential Healthcare Fund4.61% of NAV
- UTI - Healthcare Fund3.66% of NAV
- Mirae Asset Healthcare Fund3.65% of NAV
- DSP Multi Cap Fund3.32% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for ALKEM are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about ALKEM
What is the ALKEM share price?
ALKEM (ALKEM) last closed at ₹5,145.00, down 1.48% on the day. Its 52-week range is ₹4,947.00 to ₹5,890.00.
What is the market cap of ALKEM?
ALKEM has a market capitalisation of about ₹62,198 crore. Its price-to-earnings ratio is 30.1.
How are ALKEM's latest results?
ALKEM reported revenue of ₹4,552 crore for Sep 2026, up 13.8% from a year earlier. Net profit was ₹675 crore (down 11.8% year on year). Return on equity was 16.7% in Mar 2026. Promoter holding was 49.7% in Jun 2026, down 5.96 points over 8 quarters.
Who owns ALKEM?
As of Jun 2026, shareholding was: Promoter 49.7%, FII 10.42%, DII 22.63%, Public 17.25%.
How many mutual funds hold ALKEM?
205 mutual fund schemes held ALKEM in October 2026. That compares with 160 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 20 Feb 2026 · Interim Dividend - Rs. 43
- 08 Aug 2025 · Final Dividend - Rs. 8
- 14 Feb 2025 · Interim Dividend - Rs. 37
- 09 Aug 2024 · Final Dividend - Rs. 5
- 16 Feb 2024 · Interim Dividend - Rs. 35
- 10 Aug 2023 · Final Dividend - Rs. 10
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.